Abbott’s Established Pharmaceuticals Division (EPD) reported a 9% year-over-year sales growth in Q1 2026, driven by strong demand in emerging markets. Sales in Key Emerging Markets increased by 9.4%, with double-digit growth in several Latin American and Asia Pacific countries. Abbott aims to meet the rising demand for branded generic medicines through a diversified portfolio, targeting therapeutic areas like cardiometabolic and gastroenterology.
Additionally, Abbott broadened its biosimilar offerings, launching denosumab biosimilars in Thailand and Brazil, enhancing access to treatments for osteoporosis and cancer-related issues. The company has experienced a 27.9% decline in share value year to date, contrasting with a 25% drop in the industry average, and currently holds a Zacks Rank of #4 (Sell).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
